{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T07:17:00Z","timestamp":1783063020024,"version":"3.54.6"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,5,9]],"date-time":"2026-05-09T00:00:00Z","timestamp":1778284800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T00:00:00Z","timestamp":1783036800000},"content-version":"vor","delay-in-days":55,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Rheumatol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Vacuoles, E1 enzyme, X-linked, autoinflammatory somatic (VEXAS) syndrome is a recently described multisystem disease. Opportunistic infections in VEXAS syndrome are increasingly being recognized and attributed to multiple factors, including immune dysregulation due to an aberrant ubiquitination pathway, secondary effects from chronic immunosuppressive treatments and underlying patient comorbidities. Given the limited consensus on antimicrobial prophylaxis, clinical practice is heterogeneous, with varying treatment outcomes.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Case presentation<\/jats:title>\n                    <jats:p>\n                      Herein, we report a rare case of cryptococcal meningitis in a patient with treatment-refractory VEXAS syndrome, on chronic moderate-dose corticosteroids (an average of 20\u00a0mg prednisolone equivalent per day) and ruxolitinib. The patient initially presented with acute confusion and fevers, with elevated inflammatory markers and worsening cytopenia. The differential diagnoses included an acute flare of VEXAS syndrome and intercurrent infection. Further testing revealed the presence of\n                      <jats:italic>Cryptococcus neoformans<\/jats:italic>\n                      in the cerebrospinal fluid. Treatment with prolonged antifungal therapy was successful.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>The case raises important considerations, firstly regarding antimicrobial - particularly antifungal - prophylaxis given limited evidence in the literature, secondly a prompt diagnosis and treatment of cryptococcal infections, and finally regular interval screening for opportunistic infections in this vulnerable patient cohort. A multidisciplinary approach to care is required to improve morbidity and mortality from atypical infections in VEXAS syndrome.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s41927-026-00648-6","type":"journal-article","created":{"date-parts":[[2026,5,9]],"date-time":"2026-05-09T10:16:58Z","timestamp":1778321818000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Cryptococcal meningitis in a patient with VEXAS syndrome: a case report"],"prefix":"10.1186","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0868-0541","authenticated-orcid":false,"given":"Michelle Chun-Ping","family":"Lin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Day","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan","family":"Lammerink","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4103-6953","authenticated-orcid":false,"given":"Syed B.","family":"Ali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,9]]},"reference":[{"issue":"27","key":"648_CR1","doi-asserted-by":"publisher","first-page":"2628","DOI":"10.1056\/NEJMoa2026834","volume":"383","author":"DB Beck","year":"2020","unstructured":"Beck DB, Ferrada MA, Sikora KA, Ombrello AK, Collins JC, Pei W, et al. Somatic Mutations in UBA1 and Severe Adult-Onset Autoinflammatory Disease. N Engl J Med. 2020;383(27):2628\u201338.","journal-title":"N Engl J Med"},{"issue":"4","key":"648_CR2","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1001\/jama.2022.24836","volume":"329","author":"DB Beck","year":"2023","unstructured":"Beck DB, Bodian DL, Shah V, Mirshahi UL, Kim J, Ding Y, et al. Estimated Prevalence and Clinical Manifestations of UBA1 Variants Associated With VEXAS Syndrome in a Clinical Population. JAMA. 2023;329(4):318\u201324.","journal-title":"JAMA"},{"issue":"6","key":"648_CR3","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1016\/j.tcb.2013.12.003","volume":"24","author":"G Kleiger","year":"2014","unstructured":"Kleiger G, Mayor T. Perilous journey: a tour of the ubiquitin-proteasome system. Trends Cell Biol. 2014;24(6):352\u20139.","journal-title":"Trends Cell Biol"},{"issue":"10","key":"648_CR4","doi-asserted-by":"publisher","first-page":"5217","DOI":"10.1093\/rheumatology\/keaf293","volume":"64","author":"A Al-Hakim","year":"2025","unstructured":"Al-Hakim A, Goldberg S, Gaillard S, Heiblig M, Beck DB, Savic S. Clinical features in VEXAS syndrome: a systematic review. Rheumatology. 2025;64(10):5217\u201329.","journal-title":"Rheumatology"},{"issue":"1","key":"648_CR5","doi-asserted-by":"publisher","first-page":"4690","DOI":"10.1038\/s41467-025-59890-0","volume":"16","author":"H Mizumaki","year":"2025","unstructured":"Mizumaki H, Gao S, Wu Z, Gutierrez-Rodrigues F, Bissa M, Feng X, et al. In depth transcriptomic profiling defines a landscape of dysfunctional immune responses in patients with VEXAS syndrome. Nat Commun. 2025;16(1):4690.","journal-title":"Nat Commun"},{"issue":"3","key":"648_CR6","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1136\/ard-2023-224819","volume":"83","author":"B de Valence","year":"2024","unstructured":"de Valence B, Delaune M, Nguyen Y, Jachiet V, Heiblig M, Jean A, et al. Serious infections in patients with VEXAS syndrome: data from the French VEXAS registry. Ann Rheum Dis. 2024;83(3):372\u201381.","journal-title":"Ann Rheum Dis"},{"key":"648_CR7","doi-asserted-by":"crossref","unstructured":"Ali SB, Gurnari C. Infections in VEXAS: a systematic review of the literature. Curr Res Translational Med. 2025:103524.","DOI":"10.1016\/j.retram.2025.103524"},{"issue":"8","key":"648_CR8","doi-asserted-by":"publisher","first-page":"e495","DOI":"10.1016\/S1473-3099(23)00731-4","volume":"24","author":"CC Chang","year":"2024","unstructured":"Chang CC, Harrison TS, Bicanic TA, Chayakulkeeree M, Sorrell TC, Warris A, et al. Global guideline for the diagnosis and management of cryptococcosis: an initiative of the ECMM and ISHAM in cooperation with the ASM. Lancet Infect Dis. 2024;24(8):e495\u2013512.","journal-title":"Lancet Infect Dis"},{"key":"648_CR9","unstructured":"Clinical and Laboratory Standards Institute. Epidemiological cutoff values for antifungal susceptibility testing. 4 ed. Clinical and Laboratory Standards Institute (CLSI); 2022."},{"issue":"6","key":"648_CR10","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1086\/342299","volume":"35","author":"PN Newton","year":"2002","unstructured":"Newton PN, Thai LH, Tip NQ, Short JM, Chierakul W, Rajanuwong A, et al. A randomized, double-blind, placebo-controlled trial of acetazolamide for the treatment of elevated intracranial pressure in cryptococcal meningitis. Clin Infect Dis. 2002;35(6):769\u201372.","journal-title":"Clin Infect Dis"},{"issue":"17","key":"648_CR11","doi-asserted-by":"publisher","first-page":"1597","DOI":"10.1056\/NEJMra2311057","volume":"390","author":"DB Meya","year":"2024","unstructured":"Meya DB, Williamson PR. Cryptococcal Disease in Diverse Hosts. N Engl J Med. 2024;390(17):1597\u2013610.","journal-title":"N Engl J Med"},{"key":"648_CR12","doi-asserted-by":"publisher","first-page":"232470962513254","DOI":"10.1177\/23247096251325416","volume":"13","author":"J Al-Nusair","year":"2025","unstructured":"Al-Nusair J, Lim O, Alhusari L, Elghezewi A, Abdallah M, Alshal M, Pacioles T. The challenging and unique diagnosis of VEXAS syndrome: a case report. J Investig Med High Impact Case Rep. 2025;13:23247096251325416.","journal-title":"J Investig Med High Impact Case Rep"},{"issue":"7","key":"648_CR13","doi-asserted-by":"publisher","first-page":"3575","DOI":"10.4103\/jfmpc.jfmpc_2147_21","volume":"11","author":"P Gupta","year":"2022","unstructured":"Gupta P, Padhan P, Bhargava N, Behera PK, Tripathy KP, Panda SS. Spectrum of infections occurring in patients of autoimmune rheumatic diseases on treatment with biological versus conventional disease-modifying antirheumatic drugs: A comparative study. J Family Med Prim Care. 2022;11(7):3575\u201383.","journal-title":"J Family Med Prim Care"},{"issue":"3","key":"648_CR14","doi-asserted-by":"publisher","first-page":"e13709","DOI":"10.1111\/myc.13709","volume":"67","author":"L Kim","year":"2024","unstructured":"Kim L, Ferraz C, Corbisiero MF, Gorvetzian S, Franco-Paredes C, Krsak M, et al. Glucocorticoids as a risk factor for infection and adverse outcomes in non-HIV and non-transplant patients with cryptococcal meningitis. Mycoses. 2024;67(3):e13709.","journal-title":"Mycoses"},{"issue":"4","key":"648_CR15","doi-asserted-by":"publisher","first-page":"e37","DOI":"10.1093\/cid\/ciad474","volume":"78","author":"DB Chastain","year":"2024","unstructured":"Chastain DB, Spradlin M, Ahmad H, Henao-Mart\u00ednez AF. Unintended Consequences: Risk of Opportunistic Infections Associated With Long-term Glucocorticoid Therapies in Adults. Clin Infect Dis. 2024;78(4):e37\u201356.","journal-title":"Clin Infect Dis"},{"issue":"7","key":"648_CR16","doi-asserted-by":"publisher","first-page":"ofae316","DOI":"10.1093\/ofid\/ofae316","volume":"11","author":"X Li","year":"2024","unstructured":"Li X, Paccoud O, Chan KH, Yuen KY, Manchon R, Lanternier F, et al. Cryptococcosis Associated With Biologic Therapy: A Narrative Review. Open Forum Infect Dis. 2024;11(7):ofae316.","journal-title":"Open Forum Infect Dis"},{"issue":"8","key":"648_CR17","doi-asserted-by":"publisher","first-page":"e43582","DOI":"10.1371\/journal.pone.0043582","volume":"7","author":"EW Bratton","year":"2012","unstructured":"Bratton EW, El Husseini N, Chastain CA, Lee MS, Poole C, St\u00fcrmer T, et al. Comparison and temporal trends of three groups with cryptococcosis: HIV-infected, solid organ transplant, and HIV-negative\/non-transplant. PLoS ONE. 2012;7(8):e43582.","journal-title":"PLoS ONE"},{"issue":"Suppl 7","key":"648_CR18","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1111\/imj.15588","volume":"51","author":"BW Teh","year":"2021","unstructured":"Teh BW, Yeoh DK, Haeusler GM, Yannakou CK, Fleming S, Lindsay J, Slavin MA. Consensus guidelines for antifungal prophylaxis in haematological malignancy and haemopoietic stem cell transplantation, 2021. Intern Med J. 2021;51(Suppl 7):67\u201388.","journal-title":"Intern Med J"},{"issue":"2","key":"648_CR19","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1111\/ejh.13631","volume":"107","author":"A Tey","year":"2021","unstructured":"Tey A, Shaw B, Cardamone L, Shepherd S, Paul E, Rogers B, Shortt J. Risk factors for invasive fungal infection in 5-azacytidine treated patients with acute myeloid leukemia and myelodysplastic syndrome. Eur J Haematol. 2021;107(2):181\u20139.","journal-title":"Eur J Haematol"},{"issue":"1","key":"648_CR20","doi-asserted-by":"publisher","first-page":"910","DOI":"10.1038\/s41467-024-44811-4","volume":"15","author":"O Kosmider","year":"2024","unstructured":"Kosmider O, Poss\u00e9m\u00e9 C, Templ\u00e9 M, Corneau A, Carbone F, Duroyon E, et al. VEXAS syndrome is characterized by inflammasome activation and monocyte dysregulation. Nat Commun. 2024;15(1):910.","journal-title":"Nat Commun"},{"key":"648_CR21","doi-asserted-by":"crossref","unstructured":"Ribier V, Hadjadj J, Jachiet V, Mekinian A, Terrier B, Georgin-Lavialle S, et al. Mapping the infectious burden in VEXAS syndrome: a systematic review and rationale for prevention. Lancet Rheumatol. 2025.","DOI":"10.1016\/S2665-9913(25)00225-5"},{"issue":"3","key":"648_CR22","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1002\/ajh.24976","volume":"93","author":"F Lussana","year":"2018","unstructured":"Lussana F, Cattaneo M, Rambaldi A, Squizzato A. Ruxolitinib-associated infections: a systematic review and meta\u2010analysis. Am J Hematol. 2018;93(3):339\u201347.","journal-title":"Am J Hematol"},{"issue":"3","key":"648_CR23","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1111\/bjh.16174","volume":"187","author":"E Sant\u2019Antonio","year":"2019","unstructured":"Sant\u2019Antonio E, Bonifacio M, Breccia M, Rumi E. A journey through infectious risk associated with ruxolitinib. Br J Haematol. 2019;187(3):286\u201395.","journal-title":"Br J Haematol"},{"key":"648_CR24","doi-asserted-by":"crossref","unstructured":"Chiu CY, John TM, Matsuo T, Wurster S, Hicklen RS, Khattak RR, et al. Disseminated histoplasmosis in a patient with myelofibrosis on ruxolitinib: a case report and review of the literature on ruxolitinib-associated invasive fungal infections. J Fungi (Basel). 2024;10(4).","DOI":"10.3390\/jof10040264"},{"issue":"8","key":"648_CR25","doi-asserted-by":"publisher","first-page":"798","DOI":"10.1093\/cid\/cir492","volume":"53","author":"A Safdar","year":"2011","unstructured":"Safdar A, Armstrong D. Infections in Patients With Hematologic Neoplasms and Hematopoietic Stem Cell Transplantation: Neutropenia, Humoral, and Splenic Defects. Clin Infect Dis. 2011;53(8):798\u2013806.","journal-title":"Clin Infect Dis"},{"issue":"10","key":"648_CR26","doi-asserted-by":"publisher","first-page":"2379","DOI":"10.1080\/10428194.2017.1295141","volume":"58","author":"JA Trubiano","year":"2017","unstructured":"Trubiano JA, Dickinson M, Thursky KA, Spelman T, Seymour JF, Slavin MA, Worth LJ. Incidence, etiology and timing of infections following azacitidine therapy for myelodysplastic syndromes. Leuk Lymphoma. 2017;58(10):2379\u201386.","journal-title":"Leuk Lymphoma"},{"key":"648_CR27","doi-asserted-by":"publisher","first-page":"6493","DOI":"10.1182\/blood-2023-179673","volume":"142","author":"J Ontiveros-Austria","year":"2023","unstructured":"Ontiveros-Austria J, Rodriguez-Rodriguez S, Demichelis R, Lara MFG, Chavez EIA. Risk Factors Associated to Severe Episodes of Infection in Myelodysplastic Syndromes. Blood. 2023;142:6493.","journal-title":"Blood"},{"issue":"13","key":"648_CR28","first-page":"1496","volume":"140","author":"MA Ferrada","year":"2022","unstructured":"Ferrada MA, Savic S, Cardona DO, Collins JC, Alessi H, Gutierrez-Rodrigues F, et al. Translation of cytoplasmic UBA1 contributes to VEXAS syndrome pathogenesis. Blood J Am Soc Hematol. 2022;140(13):1496\u2013506.","journal-title":"Blood J Am Soc Hematol"},{"issue":"3","key":"648_CR29","doi-asserted-by":"publisher","first-page":"564","DOI":"10.1111\/bjd.20805","volume":"186","author":"S Georgin-Lavialle","year":"2022","unstructured":"Georgin-Lavialle S, Terrier B, Guedon A, Heiblig M, Comont T, Lazaro E, et al. Further characterization of clinical and laboratory features in VEXAS syndrome: large\u2010scale analysis of a multicentre case series of 116 French patients. Br J Dermatol. 2022;186(3):564\u201374.","journal-title":"Br J Dermatol"},{"key":"648_CR30","doi-asserted-by":"crossref","unstructured":"Mekinian A, Georgin-Lavialle S, Ferrada MA, Savic S, Koster MJ, Kosmider O, et al. American college of rheumatology guidance statement for diagnosis and management of VEXAS developed by the International VEXAS Working Group Expert Panel. Arthritis & Rheumatology; 2025.","DOI":"10.1016\/j.revmed.2026.03.381"},{"issue":"1","key":"648_CR31","doi-asserted-by":"publisher","first-page":"e6","DOI":"10.1016\/S2666-5247(20)30199-3","volume":"2","author":"N Papon","year":"2021","unstructured":"Papon N, Nevez G, Le Gal S, Vigneau C, Robert-Gangneux F, Bouchara J-P, et al. Fungal infections in transplant recipients: pros and cons of immunosuppressive and antimicrobial treatment. Lancet Microbe. 2021;2(1):e6\u20138.","journal-title":"Lancet Microbe"},{"issue":"8","key":"648_CR32","first-page":"Cd004773","volume":"8","author":"AA Awotiwon","year":"2018","unstructured":"Awotiwon AA, Johnson S, Rutherford GW, Meintjes G, Eshun-Wilson I. Primary antifungal prophylaxis for cryptococcal disease in HIV-positive people. Cochrane Database Syst Rev. 2018;8(8):Cd004773.","journal-title":"Cochrane Database Syst Rev"},{"issue":"6","key":"648_CR33","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1016\/j.anai.2023.01.010","volume":"130","author":"SS Mustafa","year":"2023","unstructured":"Mustafa SS. Steroid-induced secondary immune deficiency. Ann Allergy Asthma Immunol. 2023;130(6):713\u20137.","journal-title":"Ann Allergy Asthma Immunol"},{"key":"648_CR34","doi-asserted-by":"crossref","unstructured":"Lee E, Miller C, Ataya A, Wang T, editors. Opportunistic infection associated with elevated GM-CSF autoantibodies: a case series and review of the literature. Open Forum Infectious Diseases; 2022: Oxford University Press US.","DOI":"10.1093\/ofid\/ofac146"},{"issue":"5","key":"648_CR35","doi-asserted-by":"publisher","first-page":"660","DOI":"10.1016\/j.cmi.2024.01.018","volume":"30","author":"Y-K Jiang","year":"2024","unstructured":"Jiang Y-K, Zhou L-H, Cheng J-H, Zhu J-H, Luo Y, Li L, et al. Anti-GM-CSF autoantibodies predict outcome of cryptococcal meningitis in patients not infected with HIV: A cohort study. Clin Microbiol Infect. 2024;30(5):660\u20135.","journal-title":"Clin Microbiol Infect"},{"issue":"11","key":"648_CR36","doi-asserted-by":"publisher","first-page":"3565","DOI":"10.1007\/s10067-024-07160-7","volume":"43","author":"SB Ali","year":"2024","unstructured":"Ali SB, Gurnari C. Allogenic haematopoietic stem cell transplantation in VEXAS: A review of 33 patients. Clin Rheumatol. 2024;43(11):3565\u201375.","journal-title":"Clin Rheumatol"},{"issue":"4","key":"648_CR37","doi-asserted-by":"publisher","first-page":"969","DOI":"10.1111\/bjh.17893","volume":"196","author":"T Comont","year":"2022","unstructured":"Comont T, Heiblig M, Rivi\u00e8re E, Terriou L, Rossignol J, Bouscary D, et al. Azacitidine for patients with Vacuoles, E1 Enzyme, X-linked, Autoinflammatory, Somatic syndrome (VEXAS) and myelodysplastic syndrome: data from the French VEXAS registry. Br J Haematol. 2022;196(4):969\u201374.","journal-title":"Br J Haematol"},{"key":"648_CR38","unstructured":"Jachiet V, Kosmider O, Beydon M, Hadjadj J, Zhao LP, Grobost V, et al. Efficacy and safety of azacitidine for VEXAS syndrome: a large-scale retrospective study from the FRENVEX group. Blood. 2025."}],"container-title":["BMC Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s41927-026-00648-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s41927-026-00648-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s41927-026-00648-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T06:34:28Z","timestamp":1783060468000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s41927-026-00648-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,9]]},"references-count":38,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["648"],"URL":"https:\/\/doi.org\/10.1186\/s41927-026-00648-6","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-7582383\/v1","asserted-by":"object"}]},"ISSN":["2520-1026"],"issn-type":[{"value":"2520-1026","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,9]]},"assertion":[{"value":"10 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Ethical approval for this case report was obtained from the Southern Adelaide Clinical Human Research Ethics Committee (SAC HREC) on 30th July 2025.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"The authors confirm that written informed consent was obtained from the patient for the publication of this manuscript and accompanying images.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"55"}}